Pancreatic Cancer Research

ResearcherRutgers, The State University of New JerseyActive in the last 2 years

Mihir Maheshkumar Shah

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4665-5534; OpenAlex author ID A5090249970, A5125606112. Sources: ClinicalTrials.gov.

Their work

Papers
16 (first author 2, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
45
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 trial · 2025: 2 papers · 2026: 4 papers

Papers 16

  1. High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1697↗
  2. Optimal Timing of Adjuvant Therapy in Patients with Poorly Differentiated Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19132-z↗
  3. ASO Author Reflections: Adjuvant Chemotherapy in Poorly Differentiated Pancreatic Ductal Adenocarcinoma: Does Timing Impact Survival? First author DOI 10.1245/s10434-026-19252-6↗
  4. ASO Visual Abstract: Optimal Timing of Adjuvant Therapy for Patients with Poorly Differentiated Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19311-y↗
  5. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  6. Ethics of Informed Consent with Comprehension of Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Last author PMID 41835444↗
  7. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  8. Landmark Series: Importance of Pancreatic Resection Margins Response to Comments to the Editor-Resection Margins Assessment by Intraoperative Flow Cytometry in… Co-author DOI 10.1245/s10434-022-11648-4↗
  9. The Impact of Carbohydrate Antigen 19-9 on Survival in Patients with Clinical Stage I and II Pancreatic Cancer. Last author DOI 10.1245/s10434-022-12497-x↗
  10. ASO Author Reflections: Pretreatment CA 19-9 Threshold of 98 U/mL is a Reasonable Cutoff for Prognostication of Clinical Stage I and II Pancreatic Cancer. Last author DOI 10.1245/s10434-022-12541-w↗
  11. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. Co-author DOI 10.1001/jamasurg.2020.5676↗
  12. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  13. ASO Author Reflections: Chemoradiation as the Mainstay of Therapy for Nonagenarians with Pancreatic Cancer. Last author DOI 10.1245/s10434-020-09319-3↗
  14. Subcategorizing T1 Staging in Pancreatic Adenocarcinoma Predicts Survival in Patients Undergoing Resection: An Analysis of the National Cancer Database. Co-author DOI 10.1089/pancan.2019.0017↗
  15. A Novel Model of Pancreatic Cancer Dormancy Reveals Mechanistic Insights and a Dormancy Gene Signature with Human Relevance Co-author DOI 10.1101/2020.04.13.037374↗
  16. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. First author DOI 10.21037/apc.2018.07.05↗

Trials 1

  1. Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy Principal investigator NCT06595160↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David A. Kooby · 6 shared papers, 2021–2026 · strength 1.59
  2. Parit T. Mavani · 3 shared papers, 2025–2026 · strength 0.97
  3. Juan Manuel Sarmiento · 3 shared papers, 2026 · strength 0.83
  4. Darren R. Carpizo · 5 shared papers, 2018–2022 · strength 0.68
  5. Shishir Kumar Maithel · 3 shared papers, 2021–2026 · strength 0.64
  6. Mokshal Shah · 1 shared paper, 2026 · strength 0.63
  7. Theresa Wicklin Gillespie · 2 shared papers, 2026 · strength 0.60
  8. Alexa D. Melucci · 2 shared papers, 2022 · strength 0.41
  9. Nipun B. Merchant · 2 shared papers, 2021–2025 · strength 0.34
  10. Jashodeep Datta · 2 shared papers, 2021–2025 · strength 0.34
  11. Anthony Casabianca · 2 shared papers, 2020–2022 · strength 0.24
  12. Chrystal M Paulos · 1 shared paper, 2026 · strength 0.23
  13. Emily R. Greene · 1 shared paper, 2026 · strength 0.23
  14. Cameron J. Herting · 1 shared paper, 2026 · strength 0.23
  15. Alyssa M. Krasinskas · 1 shared paper, 2026 · strength 0.23
  16. Natalie K. Horvat · 1 shared paper, 2026 · strength 0.23
  17. Olatunji Boladale Alese · 1 shared paper, 2026 · strength 0.23
  18. Gregory B. Lesinski · 1 shared paper, 2026 · strength 0.23
  19. Maria Diab · 1 shared paper, 2026 · strength 0.23
  20. Bassel F. El‐Rayes · 1 shared paper, 2026 · strength 0.23
  21. Rebecca S. Meltzer · 1 shared paper, 2021 · strength 0.22
  22. Benjamin A. Y. Cher · 1 shared paper, 2025 · strength 0.19
  23. Alexander A. Parikh · 1 shared paper, 2025 · strength 0.19
  24. Daniel Erik Abbott · 1 shared paper, 2025 · strength 0.19
  25. Syed Ameen Ahmad · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.